In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.

[1]  N. Bohnen,et al.  Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[2]  S. Teipel,et al.  Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease , 2020, Neurology.

[3]  J. Kulisevsky,et al.  Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker. , 2019, Parkinsonism & related disorders.

[4]  T. Druzgal,et al.  Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  Stefan Teipel,et al.  The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles , 2018, Human brain mapping.

[6]  S. Lehéricy,et al.  Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[7]  A. Strafella,et al.  Brain degeneration in Parkinson’s disease patients with cognitive decline: a coordinate-based meta-analysis , 2018, Brain Imaging and Behavior.

[8]  M. Politis,et al.  Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson’s disease , 2018, Brain : a journal of neurology.

[9]  Nicola J. Ray,et al.  Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia , 2018, Current Geriatrics Reports.

[10]  Nicola J. Ray,et al.  In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s disease , 2017, Brain : a journal of neurology.

[11]  L. Grinberg,et al.  In Vivo Volumetry of the Cholinergic Basal Forebrain , 2018 .

[12]  C. Normann,et al.  Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment , 2016, Journal of Alzheimer's disease : JAD.

[13]  J. Kulisevsky,et al.  COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression , 2016, BMC Neurology.

[14]  N. Schuff,et al.  Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection , 2015, The Lancet Neurology.

[15]  S. Gentleman,et al.  Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease , 2015, Acta Neuropathologica.

[16]  Richard A Armstrong,et al.  When to use the Bonferroni correction , 2014, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[17]  Stefan J. Teipel,et al.  Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia , 2014, Journal of Neurology.

[18]  Y. Sohn,et al.  Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  Y. Sohn,et al.  Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status , 2012, Neurobiology of Aging.

[20]  F. Piras,et al.  Hippocampal abnormalities and memory deficits in Parkinson disease , 2012, Neurology.

[21]  H. Heinsen,et al.  Atrophy of the Cholinergic Basal Forebrain Over the Adult Age Range and in Early Stages of Alzheimer's Disease , 2012, Biological Psychiatry.

[22]  Stefan Klöppel,et al.  Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study , 2011, Psychiatry Research: Neuroimaging.

[23]  T. Anderson,et al.  Grey matter atrophy in cognitively impaired Parkinson's disease , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  R. Albin,et al.  Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease , 2010, Brain : a journal of neurology.

[25]  Jaime Kulisevsky,et al.  Parkinson's disease‐cognitive rating scale: A new cognitive scale specific for Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[26]  H. Hanyu,et al.  MR features of the substantia innominata and therapeutic implications in dementias , 2007, Neurobiology of Aging.

[27]  H. Hanyu,et al.  Differences in MR features of the substantia innominata between dementia with Lewy bodies and Alzheimer’s disease , 2005, Journal of Neurology.

[28]  I. McKeith,et al.  Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. , 2004, Brain : a journal of neurology.